Next Phase Newsletter

A firm is focused on investing in early-stage companies with disruptive technologies and is actively seeking entrepreneurs with a track record of success. The firm’s primary focus includes robotics, biotechnology, hardware, artificial intelligence, blockchain, novel materials, and other advanced technologies. The firm invests in seed round and Series A round, the typical investment is between $100,000 and $500,000. The firm is supported by well-established Chinese partners. The firm strives to assist their portfolio companies in reaching a global market.

The firm’s primary focus includes robotics, biotechnology, hardware, artificial intelligence, blockchain, novel materials, and other advanced technologies.

The firm is looking for founders with strong academic credentials and sector expertise. The firm actively seek entrepreneurs with a track record of success.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

The VC is a human longevity-focused VC firm based in New York, USA. The firm invests in Pre-seed, Seed, Seed+ companies at $200K with a possible follow-on of $400K and Series A & B rounds at $800K with a

potential $1.6M follow-on. The firm will consider opportunities primarily in the Americas, UK, and EU. Also, the firm actively supports companies by providing connections to human capital providers, governmental entities, and suitable investors to help founders grow their business.

The firm will look at a broad spectrum of products and services within space technology and human longevity. The partners had previously invested in 20+ early-stage technology companies/ funds with active private deal-flow in the verticals of space, healthcare, and robotics. The firm is investing in biomarkers, diagnostics, digital health, and therapeutics (RX and OTC), dealing with the hallmarks of aging on the longevity side of things.

The firm will invest in privately held companies only and will participate as a co-investor. The firm prefers to invest in companies with at least three founders and will not invest in sole founder companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The fund is the corporate venture arm of an Australian-based company with an interest in infection prevention technology, primarily in the hospital setting. The firm is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products into the market. Within the area of infection prevention and control, the fund will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm will invest globally.

The firm has a focus on digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare acquired infection.

The fund will only make strategic investments that align with the corporate vision. The firm is an active investor, and will typically take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Japanese pharmaceutical company is dedicated to research, development, and commercialization of innovative products for unmet medical needs in the areas of musculoskeletal disorders, including pain management and critical care. The company is vastly investing to expand their presence from its domestic roots in Japan to become a Global Specialty Pharma. To achieve above goal, the company is looking for opportunities of early stage pipelines and/or research collaborations with global rights to expand their business worldwide.

The company Is pursuing attractive, new in-licensing and research collaboration opportunities in the following areas of interest: in relation to in-licensing opportunities in pre-clinical stage for the global market, the company is interested in chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, and muscle-related disorders (i.e. DMD, ALS, etc.) In relation to research collaboration opportunities for the global market, the company is interested in drug seeds for chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, as well as platform technologies related to drug delivery, formulation, excipients, oral, transdermal, nanoparticle, controlled release, and targeting.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm will seek global rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An investment firm based in the USA manages corporate venture funds of a large health system and  looks to invest in companies of strategic interest to its major health plan investors while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed fund in collaboration with a major China venture capital firm manages over $1B has both USD funds and CNY funds. The firm has invested in over 700 portfolio companies, including over 60 life science companies. While open to growth stage companies, the firm prefers to get involved as early as possible, and ideally be the first institutional investor for its portfolio company. Initial sizes of investment can largely vary, but a typical allocation size is between $1 MM to $2 MM. The firm is very entrepreneurs friendly, and invests in companies across the globe.

The firm has a general interest in Therapeutics, Digital Health, MedTech, and Diagnostics.

The firm believes that great businesses start with exceptional founding teams and values the management team of a start-up more than anything else. The firm prefers companies with a Chinese angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA based fund supports and advances life science technologies from early development through clinical proof-of-concept. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development.

The size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the fund can invest directly as a Series A investment along with participation in related Series B investments.  The firm is open to global opportunities.

The firm supports opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, the firm is open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly, supportive of first-time CEOs, and works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.